# Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors

> Kiniksa Pharmaceuticals raises 2026 revenue guidance to $1.045B-$1.050B as ARCALYST sales surge.
- Title: Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term…
- Summary: Kiniksa Pharmaceuticals raises 2026 revenue guidance to $1.045B-$1.050B as ARCALYST sales surge. Kiniksa Pharmaceuticals increased full-year 2026 revenue…
- Keywords: kiniksa, arcalyst, revenue, pharmaceuticals, 2026, quarterly, pipeline, finance, money, Key, Takeaways, Long-Term
- Source: The Motley Fool — https://fool.com/earnings/takeaways/2026/10/27/kiniksa-pharmaceuticals-3-key-takeaways-for-long-term-investors
- Author: The Motley Fool Team
- Published: 2026-10-27T17:51:15+00:00
- Read time: 1 min
- Topics: kiniksa, arcalyst, revenue, pharmaceuticals, 2026, quarterly, pipeline, finance, money
## Q3 2026 Earnings Call
Kiniksa Pharmaceuticals raised full-year 2026 revenue guidance to $1.045 billion-$1.050 billion.
## ARCALYST Sales Surpassed Guidance
ARCALYST revenue grew 58% year-over-year to $286 million in Q3 2026.

> ARCALYST revenue grew 58% year-over-year to $286 million in the third quarter
## AI-Targeted Marketing Campaign
Heart's Home campaign increased ARCALYST website traffic 12-fold compared to baseline.

> we've seen a 12-fold increase in the traffic to our ARCALYST website compared to baseline levels
## Pipeline Candidates Target Less Frequent Dosing
KPL-387 and KPL-1161 pipeline candidates target less frequent dosing schedules.

> The pivotal phase III study with KPL-387 continues to enroll and dose patients
## Key takeaway

Kiniksa Pharmaceuticals increased full-year 2026 revenue guidance to $1.045 billion-$1.050 billion after ARCALYST sales grew 58% year-over-year to $286 million.